InMed CEO, Eric A. Adams, is asked by Shadd Dales of The Dales Repot whether the cost of rare cannabinoids is scalable enough to entice big consumer product companies.
Read the article and watch the full video at The Dales Report.
Fierce Biotech Article: Neuroinflammation a Key Underlying Factor in Alzheimer’s Disease Risk
Article featured in Fierce Biotech October 16, 2025 Excerpt: New findings discussed at the latest Alzheimer’s Association International Conference (AAIC) highlight the risk factors associated
October 27, 2025
